



# Kent Academic Repository

Wu, Di, Mehdipour, Ahmad R, Finke, Franziska, Goojani, Hojjat G, Groh, Roan R, Grund, Tamara M, Reichhart, Thomas MB, Zimmermann, Rita, Welsch, Sonja, Bald, Dirk and others (2023) *Dissecting the conformational complexity and mechanism of a bacterial heme transporter*. Nature Chemical Biology . ISSN 1552-4450.

## Downloaded from

<https://kar.kent.ac.uk/100784/> The University of Kent's Academic Repository KAR

## The version of record is available from

<https://doi.org/10.1038/s41589-023-01314-5>

## This document version

Publisher pdf

## DOI for this version

## Licence for this version

CC BY (Attribution)

## Additional information

## Versions of research works

### Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

### Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in **Title of Journal**, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

### Enquiries

If you have questions about this document contact [ResearchSupport@kent.ac.uk](mailto:ResearchSupport@kent.ac.uk). Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

# Dissecting the conformational complexity and mechanism of a bacterial heme transporter

Received: 19 September 2022

Accepted: 14 March 2023

Published online: 24 April 2023

 Check for updates

Di Wu<sup>1</sup>, Ahmad R. Mehdipour<sup>2,3</sup>, Franziska Finke<sup>1</sup>, Hojjat G. Goojani<sup>4</sup>,  
Roan R. Groh<sup>1</sup>, Tamara N. Grund<sup>1</sup>, Thomas M. B. Reichhart<sup>1</sup>, Rita Zimmermann<sup>1</sup>,  
Sonja Welsch<sup>5</sup>, Dirk Bald<sup>4</sup>, Mark Shepherd<sup>6</sup>, Gerhard Hummer<sup>2,7</sup> &  
Schara Safarian<sup>1,8,9</sup>✉

Iron-bound cyclic tetrapyrroles (hemes) are redox-active cofactors in bioenergetic enzymes. However, the mechanisms of heme transport and insertion into respiratory chain complexes remain unclear. Here, we used cellular, biochemical, structural and computational methods to characterize the structure and function of the heterodimeric bacterial ABC transporter CydDC. We provide multi-level evidence that CydDC is a heme transporter required for functional maturation of cytochrome *bd*, a pharmaceutically relevant drug target. Our systematic single-particle cryogenic-electron microscopy approach combined with atomistic molecular dynamics simulations provides detailed insight into the conformational landscape of CydDC during substrate binding and occlusion. Our simulations reveal that heme binds laterally from the membrane space to the transmembrane region of CydDC, enabled by a highly asymmetrical inward-facing CydDC conformation. During the binding process, heme propionates interact with positively charged residues on the surface and later in the substrate-binding pocket of the transporter, causing the heme orientation to rotate 180°.

Iron is the second most abundant metal on our planet and an essential trace element for all domains of life<sup>1–6</sup>. It is involved in a multitude of physiological processes such as photosynthesis, protein biosynthesis and respiration. Cellular iron is found in the form of iron-sulfur clusters (Fe-S), iron-bound cyclic tetrapyrroles (hemes) or in its free ionic forms. In biological systems, iron mediates electron transfer by acting as electron acceptor or donor in various biochemical reactions<sup>7</sup>. Terminal respiratory oxidases are metalloproteins that rely on their

redox-active heme cofactors for reduction of molecular oxygen to water<sup>8–15</sup>. Knowledge about the mechanism of maturation and heme insertion of cytochrome *bd*-type oxidases remains unknown but is urgently required for the development of antimicrobial drugs that can specifically target the energy metabolism and respiratory rewiring of human pathogenic bacteria upon infection and proliferation<sup>16,17</sup>.

The ABC transporter CydDC plays a central role in the biogenesis of membrane-integrated and soluble cytochromes<sup>18–22</sup>. Its precise

<sup>1</sup>Department of Molecular Membrane Biology, Max Planck Institute of Biophysics, Frankfurt/Main, Germany. <sup>2</sup>Department of Theoretical Biophysics, Max Planck Institute of Biophysics, Frankfurt/Main, Germany. <sup>3</sup>Center for Molecular Modeling (CMM), Ghent University, Zwijnaarde, Belgium. <sup>4</sup>Amsterdam Institute for Life and Environment (A-LIFE), AIMMS, Faculty of Science, Vrije University of Amsterdam, Amsterdam, the Netherlands. <sup>5</sup>Central Electron Microscopy Facility, Max Planck Institute of Biophysics, Frankfurt am Main, Germany. <sup>6</sup>School of Biosciences, RAPID Group, University of Kent, Canterbury, UK. <sup>7</sup>Institute of Biophysics, Goethe University Frankfurt, Frankfurt/Main, Germany. <sup>8</sup>Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. <sup>9</sup>Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt/Main, Germany. ✉e-mail: [schara.safarian@biophys.mpg.de](mailto:schara.safarian@biophys.mpg.de)

function and molecular mode of action have remained enigmatic for decades<sup>23,24</sup>. CydDC was initially thought to translocate heme across the bacterial cytoplasmic membrane. Follow-up studies, however, concluded that CydDC might be involved in the regulation of the periplasmic redox poise by transporting the reductants glutathione (GSH) and L-cysteine (L-Cys) to the periplasm<sup>19,21,25–28</sup>. Despite this widely accepted substrate specificity of CydDC, it was later found that the CydDC complex copurifies with bound heme<sup>29</sup>. This observation motivated the assumption that heme represents a prosthetic group of a periplasmic redox sensor domain for regulation of transporter activity<sup>18,23</sup>. A recent work challenged the transporter function of CydDC and proposed that it operates as a cystine reductase<sup>30</sup>.

To resolve these points of controversy, we used *Escherichia coli* (*E. coli*) as a model system amenable to our integrative approach including growth-complementation studies, biochemical activity assays, systematic single-particle cryogenic-electron microscopy (cryo-EM) and atomistic molecular dynamics (MD) simulations to characterize the structure and function of CydDC down to the molecular level.

## Results

### CydDC function is linked to biogenesis of cytochrome *bd*

We performed growth-complementation studies using the *E. coli* mutant strain MB43, which lacks all terminal oxidases and thus shows impaired respiratory activity (Fig. 1)<sup>31</sup>. The growth of this strain is poor compared to wild-type controls, but was improved following the introduction of genes encoding cytochromes *bd*-I (*pcyDABX*) or *bd*-II (*pappCBX*) (Fig. 1a and Supplementary Fig. 1). Next, we constructed an isogenic deletion mutant of the *cydDC* operon in the genetic background of MB43. This strain (MB43 $\Delta$ *cydDC*) shows an indistinguishable phenotype to MB43 (Fig. 1a). Unlike MB43, the growth of MB43 $\Delta$ *cydDC* was not restored by introducing *pcyDABX* or *pappCBX*. A growth-active phenotype of MB43 $\Delta$ *cydDC* was only achieved by double complementation with *pcyDABX* and either *pcyDABX* or *pappCBX* (Fig. 1a). Accordingly, ultraviolet-visible light (UV-vis) spectroscopy revealed that the characteristic fingerprints of cytochrome *bd* cofactors (hemes *b* and *d*) were absent in membrane fractions of MB43 and MB43 $\Delta$ *cydDC* but clearly detected in the growth-restored complementation strains (Fig. 1b)<sup>31–34</sup>.

Further, we confirmed oxygen reductase activity of membrane fractions from growth-restored MB43 and MB43 $\Delta$ *cydDC* variants (Fig. 1c and Supplementary Fig. 2a). Finally, we used the highly specific inhibitor aurachin D to demonstrate that restored oxygen consumption was due to the activity of cytochrome *bd* variants (Fig. 1c). In summary, growth-complementation studies, UV-vis spectroscopy and oxygen consumption assays confirmed that CydDC is essential for the functional maturation of both known variants of cytochrome *bd* of *E. coli* (Fig. 1f).

### ATPase activity of CydDC is stimulated by heme

We next tested affinity-purified CydDC for ATPase activity in the presence of putative substrates, primarily using the malachite green phosphate assay (Fig. 1d and Supplementary Fig. 3)<sup>26,29,30,35</sup>. In contrast to previous reports, we found that GSH and L-Cys failed to induce hydrolysis, whereas heme stimulated the ATPase activity of CydDC in a concentration-dependent manner (Fig. 1d,e and Extended Data Fig. 1). This effect was only observed for heme itself, but not for its macrocyclic scaffold protoporphyrin IX or free iron, suggesting that the complexed iron molecule might play a critical role in binding and coordination (Fig. 1d). For verification of our results, we used a second conceptually different enzyme-coupled ATP hydrolysis assay (Extended Data Fig. 2a). Both assays confirm the ATPase stimulating effect of heme while showing that the tested reductants do not show typical effects of ABC transporter substrates. To bolster our finding of heme as a primary candidate for a substrate molecule of CydDC, we determined kinetic parameters for heme and ATP. We obtained  $K_M^{\text{app}}$  values of 79.7 nM for heme, and 91.9  $\mu$ M for ATP (Fig. 1e and Extended Data Fig. 2b,c).

These values are reasonable regarding the physiological occurrence of both substrates<sup>36,37</sup>.

Next, we generated glutamate to glutamine mutants of the Walker B domains of CydD and CydC to determine whether CydDC possesses a functionally degenerate nucleotide-binding domain (NBD) as found in other ABC transporters<sup>38</sup>. Of the two constructed Walker B variants, only CydDC<sup>E500Q</sup> could be isolated in sufficient yield, purity and stability (Supplementary Fig. 3). Using heme as substrate, we showed that the conserved Walker B glutamate of CydC is essential for ATPase activity of CydDC (Fig. 1d and Extended Data Fig. 3a,b). Complementation of MB43 $\Delta$ *cydDC* with the gene product of *pE500Q* (CydC<sup>E500Q</sup>) in combination with either *pcyDABX* or *pappCBX* did not restore bacterial growth (Fig. 1a,b and Supplementary Fig. 2b,c). We thus conclude that NBD<sup>C</sup> represents the canonical hydrolysis site and that CydD most presumably contains a degenerate NBD.

To verify our findings on the role of heme as a potential substrate molecule and to dissect the molecular basis of CydDC function, we designed a matrix of sample conditions based on a combination of putative substrate molecules, nucleotides that are either susceptible or resistant to hydrolysis and rationally designed mutant variants of CydDC. In total, we determined single-particle cryo-EM structures of CydDC under 23 different conditions at resolutions of 2.7 to 3.9 Å (Supplementary Table 1 and Supplementary Figs. 3–9).

### Overall architecture and insights into substrate specificity


The nucleotide and substrate-free, inward-facing conformation of CydDC (IF<sup>apo</sup><sub>as isolated</sub>), obtained in as isolated conditions, exhibits canonical features of type IV ABC transporters (Fig. 2a,b)<sup>39–41</sup>. Each subunit is composed of a membrane domain formed by six transmembrane  $\alpha$ -helices (TMH), an N-terminal cytoplasmic elbow helix oriented parallel to the membrane plane and a cytoplasmic NBD (Fig. 2a,b)<sup>42</sup>. In this conformation the heterodimer adopts an asymmetrical structure (C $\alpha$  r.m.s.d. of 4.17 Å) (Supplementary Fig. 10).

The successful determination of the IF<sup>apo</sup><sub>as isolated</sub> conformation was followed by a screen for substrate molecules binding to CydDC (Fig. 2c). Of all tested compounds, we were only able to identify ligand density of heme bound within the TMH domain (Extended Data Fig. 4). We obtained heme bound CydDC conformations not only through exogenous heme addition, but consistently also from subsets of CydDC particles that natively copurified with heme in sample compositions free of heme (Fig. 2c).

In addition, we determined structures of CydDC in the presence of a combination of heme and thiols (GSH, glutathione disulfide (GSSG), L-Cys) to assess whether these molecules may be heme-dependent cosubstrates. However, we could identify ligand density only for heme but did not observe signal for any other added molecule.

### Heme binding induces sequential conformational transitions

From the sum of analyzed sample conditions, we obtained three heme-bound states that provide comprehensive insight into substrate binding and occlusion (Figs. 2c and 3, Extended Data Fig. 4 and Supplementary Fig. 11). Heme initially binds within a cavity formed by transmembrane helices TM2<sup>C</sup>, TM3<sup>C</sup>, TM5<sup>D</sup> and TM6<sup>D</sup> that is in the vicinity of the lateral membrane plane (Fig. 3a, Extended Data Fig. 4a and Supplementary Fig. 11). In this IF<sup>heme</sup><sub>bound</sub> conformation, which was obtained exclusively under active turnover, the heme molecule primarily interacts with the invariant H85<sup>C</sup> residue that functions as an axial ligand for the heme iron at a distance of 3.4 Å (Figs. 2c and 3a). Additionally, the two heme propionate groups form electrostatic interactions with R81<sup>C</sup> of TM2<sup>C</sup> and R136<sup>C</sup> of TM3<sup>C</sup>, respectively (Fig. 3a, Extended Data Fig. 4a, Supplementary Fig. 11 and Supplementary Video 1). We assign the IF<sup>heme</sup><sub>coordinated</sub> state as the second step in the binding cascade. Here, the interaction between CydDC and heme is strengthened by movement of the C-terminal segment of TM6<sup>D</sup> toward the heme and concomitant side chain rearrangements of H312<sup>D</sup>, which acts as a second




**Fig. 1 | Physiological and biochemical links between CydDC activity and cytochrome *bd* biogenesis. a**, *E. coli* growth-complementation studies. Plasmid encoded cytochrome *bd* variants were *pcydABX*, *cyt. bd-I*; *pappCBX*, *cyt. bd-II*. Plasmid encoded *CydDC* variants were *pcydDC*, wild-type; *pE500Q*, E→Q exchange at position 500 of *CydC*; *pH85A*, H→A exchange at position 85 of *CydC*. Control plasmid was pcontrol, empty pET17 vector. Data are presented as mean values  $\pm$  s.d. ( $n = 3$  biological replicates). **b**, Reduced-minus-oxidized UV-vis spectra of membrane fractions from strains with restored and/or impaired growth phenotypes. **c**, Oxygen reductase activity of membranes from strains with growth-active phenotypes. Aurachin D (Aur. D) induced inhibition of oxygen consumption indicates for cytochrome *bd* specific oxygen reductase activity. Data are presented as mean values  $\pm$  s.d. ( $n = 3$  biological replicates). Significance

was assessed based on a paired two-tailed Student's *t*-test. **d**, Stimulation of ATP hydrolysis activity (malachite green phosphate assay) of *CydDC*. Significance was assessed based on a paired two-tailed Student's *t*-test. All presented ATP hydrolysis data are corrected for background activity in the absence of substrate candidates. Data are presented as mean values  $\pm$  s.d. ( $n = 3$  assay technical replicates). CSSC, cystine; GSSG, glutathione disulfide; P-IX, protoporphyrin IX. **e**, Titration experiments for the determination of Michaelis constants ( $K_M^{app}$ ) for ATP ( $91.9 \pm 9.7 \mu\text{M}$ ) and heme ( $79.7 \pm 1.2 \text{ nM}$ ). All presented ATP hydrolysis data are corrected for background activity in the absence of substrate candidates. Data are presented as mean values  $\pm$  s.d. ( $n = 3$  assay technical replicates). **f**, Working model of the physiological role of *CydDC* based on independent physiological and biochemical data generated in this study.

axial ligand of the heme iron, and Y311<sup>D</sup>, which moves in front of the porphyrin plane and thereby prevents heme from escaping to the membrane space (Fig. 3a, Extended Data Fig. 4a, Supplementary Fig. 11 and Supplementary Videos 2 and 3). The interaction between TM6<sup>D</sup> and EL<sup>D</sup> (elbow helix) further causes positioning of the elbow helix closer toward TM4<sup>D</sup>, which narrows the membrane-accessible gate to the heme-binding site (Fig. 3d, Extended Data Fig. 4a, Supplementary Fig. 12 and Supplementary Videos 2 and 3).

The most abundant heme-bound conformation observed in our study is termed IF<sub>confined</sub><sup>heme</sup> and represents the confined inward-facing TMH conformation (Figs. 2c and 3a). On binding and tight coordination of heme, a crucial conformational change of TM4<sup>D</sup> is induced (Supplementary Video 4). Movement of this 7.2 nm long helix occurs on two levels (Supplementary Videos 5 and 6). The membrane-embedded segment of TM4<sup>D</sup> (segments 164–195) changes its angle from roughly 60° to 75° relative to the membrane plane and thus moves in front of



**Fig. 2 | Systematic cryo-EM approach. a**, Volume map representation of the IF<sup>heme</sup> structure representing the general architecture of CydDC. Dark green, CydC; light green, CydD. The left shows a cross-section of the membrane domain composed of 12 TMs displaying arrangement and geometry typical for type IV ABC transporters. The right shows a cross-section of NBDs. The subdomains ABC $\alpha$  and ABC $\beta$  of each NBD are highlighted. **b**, Schematic organization of CydC and CydD subunits. TMs are indicated by numbers. Residues important for ATP hydrolysis and signal transduction between TMH and NB domains are highlighted. **c**, Summary of systematic single-particle cryo-EM studies. The left

shows volume maps and corresponding ribbon models. Each circle represents a distinct conformation of CydDC. Numbers around circles refer to sample condition of CydDC analyzed by electron microscopy. Bold numbers indicate that the given conformation was present under that condition. The right shows a summarized information panel about the analyzed CydDC variants, presence and absence of heme, nucleotide and additional putative substrate molecules. CydDC<sup>WT</sup>, beige; CydDC<sup>H85A</sup>, light blue; CydDC<sup>E500Q</sup>, purple. IF, inward-facing; Occ, occluded; GSSG, glutathione disulfide; CSSC, cystine.

the heme, blocking the lateral membrane gate (Fig. 3b,c). The kinked C-terminal half of TM4<sup>D</sup> that is exposed to the cytoplasm concomitantly moves toward EL<sup>D</sup> and adopts a conformation that runs diagonally above the bound heme molecule (Fig. 3d). Accordingly, the side chain of F195<sup>D</sup> moves in front of the heme and aligns in parallel with the porphyrin plane (Fig. 3a,c and Supplementary Fig. 11). Together with Y311 of TM6<sup>D</sup>, these aromatic residues generate  $\pi$ - $\pi$  stacking interactions with the porphyrin plane of the heme. An electrostatic interaction network formed between EL<sup>D</sup> and TM4 further contributes to the formation of a tightly sealed substrate access gate (Fig. 3a,c, Supplementary Figs. 11 and 12 and Supplementary Video 5). The formation of a

distinct heme-binding pocket narrows the unoccupied space within the TMH domain and establishes a lateral pathway perpendicular to the membrane plane that ends at the tightly interlocked periplasmic substrate exit gate (Fig. 3a). Furthermore, we observed that binding and confinement of heme occurs independent of nucleotide occupancy of the NBDs (Fig. 2c).

Based on the deduced sequence of binding events and the distinct interaction patterns between heme and CydDC, we reasoned that the interaction between H85<sup>C</sup> and the heme iron marks the most crucial step of substrate recognition. To test this hypothesis, we generated a CydDC H85A<sup>C</sup> mutant and performed growth-restoring

complementation studies and oxygen consumption measurements (Fig. 1a,b and Supplementary Fig. 2b,c). In addition, we investigated the effect of the histidine to alanine replacement on ATP hydrolysis activity (Fig. 1d). A lack of this highly conserved histidine residue abrogates the functionality of CydDC (Fig. 1a,b,d, Extended Data Fig. 3c and Supplementary Fig. 2b,c). Furthermore, CydDC<sup>H85A</sup> could not be copurified with bound heme and could not be loaded by the exogenous addition of heme (Extended Data Fig. 5). These observations were confirmed by cryo-EM structures of CydDC<sup>H85A</sup>, exclusively adopting the IF<sup>apo</sup><sub>as isolated</sub> conformation, irrespective of presence or absence of exogenously added heme to the samples (Fig. 2c).

By analyzing the relationship between sample conditions and obtained CydDC conformations we recognized that the IF<sup>heme</sup><sub>coordinated</sub> conformation was obtained only in the presence of the reductants GSH and L-Cys. We reason that the systematic absence of IF<sup>heme</sup><sub>confined</sub> state in the presence of GSH and L-Cys together with the consistent observation of IF<sup>heme</sup><sub>coordinated</sub> as the major heme-bound class indicates that these reductants cause opening of the closed lateral heme entry gate. A lack of clearly distinguishable ligand density in the cryo-EM maps of the respective datasets leaves open the question about the precise interaction sites of these thiols and the underlying molecular mechanisms that result in the stabilization of the IF<sup>heme</sup><sub>coordinated</sub> conformation.

### Heme enters CydDC via the membrane and rotates by 180°

To map possible routes of heme entry, we carried out multiple atomistic MD simulations, focusing on the behavior of heme near lipid bilayer surfaces (70% palmitoyloleoyl phosphatidylethanolamine (POPE), 25% palmitoyloleoyl phosphatidylglycerol (POPG) and 5% cardiolipin) and the substrate-binding pocket (Fig. 4 and Extended Data Fig. 6). Our starting simulations showed that the porphyrin scaffold immersed deeply into the membrane core and interacted with lipid acyl chains, while the two propionate groups oriented toward the lipid head groups and interacted mostly with the ethanolamine groups of POPE molecules (Extended Data Fig. 6a). These observations are consistent with earlier experimental reports<sup>43,44</sup>.

Next, we analyzed the dynamics of heme placed near the lateral entry site of CydDC in the IF<sup>apo</sup><sub>as isolated</sub> state. Analysis of nonbonded interaction energies between heme and IF<sup>apo</sup><sub>as isolated</sub> shows that electrostatic interactions between K3<sup>D</sup>, K7<sup>D</sup>, K314<sup>D</sup> and R192<sup>D</sup> and the heme propionates play a key role in attracting heme toward the lateral entry site. These interactions keep heme in the original membrane-embedded orientation ( $\theta_z \geq 30^\circ$ ) (Fig. 4 and Supplementary Fig. 13). When we mutate the K3<sup>D</sup>, K7<sup>D</sup> and K314<sup>D</sup> to alanines, both the rotation angle ( $\theta_z$ ) increases and the distribution of the distance to the binding site ( $d_{\text{heme-H85}}$ ) is broadened (Supplementary Fig. 14). We further observe that once heme moves inside the cavity toward the defined binding pocket, its interactions with R77<sup>C</sup>, R81<sup>C</sup> and R136<sup>C</sup> become stronger while its interactions with the surface lysine groups diminish. Moreover, the interactions with R77<sup>C</sup>, R81<sup>C</sup> and R136<sup>C</sup> appear to be a key factor for driving a 90° rotation ( $\theta_z \approx 90^\circ$ ) of the heme. The mutation of R136<sup>C</sup> to alanine in the IF<sup>heme</sup><sub>confined</sub> state in the absence of axial ligation of heme narrows the conformational distribution (stronger clustering) at higher  $\theta_z$  angles showing the importance of this residue in keeping heme in the 90° rotation conformation. In this mutation (R136<sup>C</sup>A), the higher rotation angle is also linked to interactions with R77<sup>C</sup> and R81<sup>C</sup>. The conformation of heme at  $\theta_z \approx 90^\circ$  has the lowest interaction energy.

Thus, the subsequently observed second 90° rotation ( $\theta_z \approx 180^\circ$ ) might deem unfavorable if we solely consider the nonbonded interaction energy (Supplementary Fig. 13), suggesting that covalent axial ligation with two coordinating histidines may be required for a full 180° rotation. When heme is axially ligated to H85<sup>C</sup> in IF<sup>heme</sup><sub>bound</sub>, or both H85<sup>C</sup> and H312<sup>D</sup> in IF<sup>heme</sup><sub>coordinated</sub> and IF<sup>heme</sup><sub>confined</sub>, it maintains the conformation we observed in our cryo-EM structures ( $\theta_z \approx 180^\circ$ ). This is reinforced by the fact that the alanine mutations of R77<sup>C</sup> and R81<sup>C</sup> in the IF<sup>heme</sup><sub>confined</sub> conformation with heme axially coordinated by the two neighboring histidines do not change  $\theta_z$  values ( $\theta_z \approx 180^\circ$ ) (Supplementary Fig. 14).

In summary, the heme reorientation mechanism of CydDC may prime heme for directed release toward the periplasmic space or the outer membrane leaflet once the transporter adopts its outward-facing release conformation (Fig. 4b). These results indicate that CydDC operates via a trap-and-flip mechanism similar to that described for primary and secondary active lipid transporters<sup>45–49</sup>.

### Substrate release depends on ATP but not hydrolysis

Next, we aimed to characterize the mechanistic relationship between substrate transport and ATP hydrolysis. Active turnover conditions of wild-type CydDC promote two catalytic states as captured by cryo-EM: IF<sup>heme</sup><sub>bound</sub> and a highly asymmetrical heme-free inward-facing conformation with nucleotide bound to both NBDs (IF<sup>apo</sup><sub>asym</sub>) (Fig. 2c). A lack of additional conformations suggests that formation of IF<sup>heme</sup><sub>confined</sub> and subsequent translocation of heme to the periplasmic space via outward-facing conformations occurs rapidly and features short-lived intermediate states. To capture further transient conformations during the transport cycle, we performed an additional turnover cryo-EM experiment using CydDC<sup>E500Q</sup> (Figs. 1d and 2c). Owing to the lack of heme in the characterized binding site despite its presence in the sample, we assign this fully occluded conformation as the prehydrolysis return state of CydDC (Occ<sup>apo</sup><sub>return</sub>) following substrate release (Fig. 3a and Supplementary Fig. 11). In contrast to the turnover dataset of CydDC<sup>E500Q</sup>, biochemically defined CydDC<sup>E500Q</sup> cryo-EM samples revealed conformational heterogeneity reflected by structures of IF<sup>heme</sup><sub>confined</sub>, IF<sup>apo</sup><sub>as isolated</sub> and IF<sup>heme</sup><sub>confined</sub> states (Fig. 2c). In the presence of heme and ATP (turnover conditions) this heterogeneity becomes resolved by fully driving CydDC<sup>E500Q</sup> into the Occ<sup>apo</sup><sub>return</sub> state and trapping it (Fig. 2c). As this effect is not achievable by the addition of heme alone and given the substantially diminished ATPase activity of the CydDC<sup>E500Q</sup> mutant, we conclude that ATP binding but not its hydrolysis is required for the transition from Occ<sup>apo</sup><sub>return</sub> to IF<sup>heme</sup><sub>confined</sub> state via outward-facing heme-release states (Fig. 1d).

### Conformational coupling between TMHs and NBDs

The transport of heme involves changes in the inter- and intrasubunit symmetry of CydDC. The Occ<sup>apo</sup><sub>return</sub> conformation features the greatest structural asymmetry ( $C\alpha$  r.m.s.d. 5.4 Å) (Supplementary Fig. 10). Loss of symmetry between CydD and CydC in the IF<sup>apo</sup><sub>asym</sub> state is caused by the rotational movement of each subunit along the transporter's central axis perpendicular to the membrane plane (Supplementary Video 7). In this wedge-like conformation, the distal side (relative to the heme-binding domain) of CydDC moves closer together than the proximal half whereby ABC $\alpha$ <sup>C</sup> and ABC $\beta$ <sup>D</sup> form a semi-interlocked NBD dimer (Fig. 5a and Supplementary Video 7). This rearrangement increases the distance between the analogous NBDs of the proximal


### Fig. 3 | Conformational landscape of heme binding and translocation.


**a**, Close-up views of residues involved in heme binding and occlusion. Surface model cross sections and side views illustrate the changing shape and size of the internal cavity and the TMH region in different conformational states. Heme is shown as purple ball-and-stick model. EL<sup>D</sup> and TM4<sup>D</sup> are shown as tubes. **b**, On heme entry and coordination, the membrane-embedded segment of TM4<sup>D</sup> moves toward EL<sup>D</sup> and thus closes the lateral gate of CydDC. **c**, The top shows the close-up view of the heme-binding site in the IF<sup>heme</sup><sub>confined</sub> state. The bottom shows

the sequence alignments of CydD and CydC heme binding-site forming regions of representative and disease related bacteria. Conserved residues are highlighted in magenta. Conserved amino acid groups are highlighted in gray. **d**, The top shows the changing EL<sup>D</sup>-TM4<sup>D</sup> distance during the transition from IF<sup>apo</sup><sub>asym</sub> to IF<sup>heme</sup><sub>confined</sub> states. The bottom shows a close-up view of the heme entry site in IF<sup>heme</sup><sub>bound</sub> (beige) and IF<sup>heme</sup><sub>confined</sub> (magenta) states, respectively. EL, elbow helix; IF, inward-facing; Occ, occluded; asym, asymmetrical.

side, and dilates the heme-accessible membrane cavity (Figs. 3a and 5a). In CydDC, TM4<sup>D</sup> has a pivotal function during the transition from IF<sub>asym</sub><sup>apo</sup> via IF<sub>asym</sub><sup>apo</sup> to IF<sub>bound</sub><sup>heme</sup> state. As described above, the membrane-integrated segment of TM4<sup>D</sup> strongly contributes to seal-

ing the bound heme molecule from the membrane environment (Fig. 3, Extended Data Fig. 4 and Supplementary Fig. 11). Beyond this function, we found that movement and rearrangement of the cytoplasmic segment of TM4<sup>D</sup> is associated with a 25° rotation of the horizontal





**Fig. 4 | Structural dynamics of the heme binding and flipping mechanism.**

**a**, Distribution of heme rotation angle ( $\theta_z$ ) versus heme distance from the binding site at H85<sup>c</sup> ( $d_{\text{heme-H85}}$ ) in different MD simulations of CydDC.  $d_{\text{heme-H85}}$  is defined as the distance between the centers of mass of heme molecules and the side chain of H85<sup>c</sup>.  $\theta_z$  is defined as the angle between two vectors: vector 1 (black) is axis normal to the membrane and vector 2 (red) is the vector connecting Cha and

CHC atoms in heme. Representative snapshots of MD simulations showing the lateral diffusion and entry of heme to the membrane-accessible binding cavity of CydDC. **b**, Close-up views show that heme interacts with the positively charged electrostatic surface and the interior of the binding cavity of CydDC. The capital letters (A–F) represent the approximate positions of each snapshot in the cluster regions plotted in panel a.

coupling helix 2 (CH2<sup>D</sup>) connecting TM5<sup>D</sup> and TM4<sup>D</sup> (Fig. 5b). The contact of CH2<sup>D</sup> with NBD<sup>C</sup> then establishes a conformational coupling that leads to an almost parallel alignment of the two NBDs, which remain separated by roughly 6–8 Å until ATP is bound to the catalytic NBD of CydC (Fig. 5a,b and Supplementary Video 8).


#### CydDC features a unique nucleotide exchange mechanism

In  $\text{Occ}_{\text{return}}^{\text{apo}}$ , we discovered a previously unknown mode of interaction between the CydD signature loop and nucleotide bound to the canonical nucleotide-binding site (NBS) of CydC (Fig. 5c). During the asymmetrical interaction of the two NBDs on the distal side, the nucleotide is bound to NBS<sup>C</sup> and its adenine base is coordinated by Y348<sup>C</sup> of the A-loop via a  $\pi$ - $\pi$  interaction on one side, and by a  $\pi$ -cation interaction

via R485<sup>D</sup> of the signature loop from CydD on the opposite side. However, in contrast to previously described fully interlocked NBD dimers<sup>47,50</sup>, the signature loop is separated from the  $\gamma$ -phosphate of the nucleotide by 12.6 Å (Fig. 5c and Extended Data Fig. 7a). The degenerate NBS<sup>D</sup> has a similar geometry in the  $\text{IF}_{\text{asym}}^{\text{apo}}$  state, with the exception that adenine does not participate in  $\pi$ - $\pi$  stacking and  $\pi$ -cation interactions. This is because of the uncharged L365<sup>D</sup> residue at the analogous position of Y348<sup>C</sup> in the Walker A motif of CydD, and the fact that the signature loop of CydC is placed at a distance of 20 Å to NBS<sup>D</sup> (Extended Data Fig. 7a).

A peculiar and thus far unreported NBS conformation was identified in the  $\text{IF}_{\text{asym}}^{\text{apo}}$  state. The conformational coupling between substrate occlusion and signal transduction ( $\text{IF}_{\text{confined}}^{\text{heme}}$  to  $\text{IF}_{\text{asym}}^{\text{apo}}$ ) to the






**Fig. 5 | Signal transduction between TMH and NB domains. a**, Surface representation of NBD–NBD interactions in proximal and distal view. Cross-section top view on the level of the NBS shows distinctly different NBD conformations. IF<sub>confined</sub><sup>heme</sup>, blue; IF<sub>asy</sub><sup>apo</sup>, magenta; IF<sub>confined</sub><sup>heme</sup>, purple. **b**, Mechanism of conformational coupling between TMH and NB domains. Occlusion of the lateral substrate gate induces conformational changes of TMs 4 and 5 of CydD causing a rotational movement of NBD<sup>C</sup> via coupling helix 2 (CH2<sup>D</sup>). No

conformational coupling between TMs of CydC and NBD<sup>D</sup> is observable. Dark blue, CydC; light blue, CydD; dark pink, CydC; light pink, CydD. **c**, Close-up view of nucleotide-binding pockets in different conformational states and nucleotide occupancies. Conserved structural motifs of the nucleotide-binding and hydrolysis sites are highlighted. ATP, green; ADP, purple; AMP-PNP, gray; phosphate, orange; Mg<sup>2+</sup>, yellow.

NBDs results in the collapse of the NBS<sup>C</sup> region and the migration of the Walker A motif into the space originally occupied by the nucleotide phosphate groups (Fig. 5c and Supplementary Video 9). During this process, the conformation of NBS<sup>D</sup> remains mostly unchanged while the signature loop of CydC moves closer toward the nucleotide, although still separated from it by 10 Å. It is noteworthy that in none of the determined IF<sub>confined</sub><sup>heme</sup> structures, we were able to observe nucleotide bound to NBS<sup>C</sup>, even in conditions where nucleotide had been added. In contrast, in all cases where externally added nucleotides

were present in the sample, a clear density was identified at NBS<sup>D</sup>. This observation suggests that the collapsed conformation of NBS<sup>C</sup> lacks affinity for ATP or any other tested nucleotide.

Sequence analysis of critical structural motifs required for ATP hydrolysis did not reveal known mutations that would abolish ATP hydrolysis by NBD<sup>D</sup> (Extended Data Fig. 7b–d). However, the tightly interlocked conformation of IF<sub>confined</sub><sup>heme</sup> provides structural insights into differences between NBDs that may explain hydrolysis deficiency of NBD<sup>D</sup> (Figs. 5c and 6, Extended Data Fig. 7a and Supplementary



**Fig. 6 | Local environment and accessibility of NBS<sup>D</sup> and NBS<sup>C</sup>.** **a**, The top panel shows a proximal view of tightly interlocked NBDs in the Occ<sup>apo</sup><sub>return</sub> state from CydDC<sup>E500Q</sup> (datasets 18–20). The bottom panel shows close-up views of the NBS regions of CydD and CydC displaying sample condition specific differences in nucleotide occupancy. ATP densities are shown in green, AMP-PNP densities are shown in gray. Densities of CydC and CydD are shown in dark and light purple, respectively. Bound ATP at NBS<sup>C</sup> is occluded by tight interactions between the CydC A-loop and the ABC $\alpha$  region of CydD in adjacency of the adenine group. The corresponding loops at NBS<sup>D</sup> are separated widely and expose ATP bound at this

site to the solvent. **b**, The center panel shows a surface model of the interlocked NBD dimer in the Occ<sup>apo</sup><sub>return</sub> state from the turnover dataset of CydDC<sup>E500Q</sup>. The left panel shows a close-up view of ATP bound to NBS<sup>D</sup> in top and side view orientation. Residues forming the local protein environment close to the adenine head group are shown. The right panel shows a close-up view of ATP bound to NBS<sup>C</sup> in top and side view orientation. Residues forming the local protein environment close to the adenine head group are shown. ATP, green; Mg<sup>2+</sup>, yellow; CydC, dark purple; CydD, light purple.

Fig. 15). The primary difference between ATP-bound NBD<sup>D</sup> and NBD<sup>C</sup> of this prehydrolysis state is the respective distance between the switch histidine and the  $\gamma$ -phosphate of ATP. Whereas H531<sup>C</sup> is in close distance (2.9 Å) to act as a catalytic acid or base during hydrolysis, H542<sup>D</sup> is positioned in a less favorable distance of 4.4 Å to participate in polar interactions (Fig. 5c). Here, it is important to mention that when we determined the Occ<sup>apo</sup><sub>return</sub> state structure from a sample that did not include exogenously added ATP or AMP-PNP, we observed lack of bound nucleotide at NBS<sup>D</sup> but not at NBS<sup>C</sup> (Figs. 2c and 6a). Loss of the NBS<sup>D</sup> nucleotide might be possible by the presence of a solvent accessible cavity that remains open toward NBS<sup>D</sup> even with interlocked NBDs

in this conformation, whereas the tight interaction between the A-loop of CydC and ABC $\alpha$  of CydD forms an enclosed inner environment for ATP around NBS<sup>C</sup> (Fig. 6b and Supplementary Fig. 15). Given the hydrolysis deficiency of CydDC<sup>E500Q</sup> and the associated conformational differences observed between turnover datasets of the wild-type and CydDC<sup>E500Q</sup> variants, we assign the consistently copurified nucleotide bound to NBS<sup>C</sup> as ATP.

**Modeling of outward-facing substrate-release conformations**  
To complement our cryo-EM data, we modeled important but experimentally inaccessible short-lived conformational states during the

transition from  $\text{Occ}_{\text{return}}^{\text{apo}}$  to  $\text{IF}_{\text{confined}}^{\text{heme}}$ . Our simulation-based modeling allowed us to construct three transient CydDC conformations representing distinct states of the transport cycle (Extended Data Fig. 8). The  $\text{Occ}_{\text{return}}^{\text{apo}}$  state represents heme-loaded CydDC upon ATP binding with tightly interlocked NBDs. To obtain this conformation, we performed an MD simulation using the slow-growth procedure. After generating the initial  $\text{Occ}_{\text{confined}}^{\text{heme}}$  model, we performed 300 ns of simulation and analyzed the structural stability by r.m.s.d. evolution and conformation dynamics. Our final model shows that the transition from  $\text{Occ}_{\text{confined}}^{\text{heme}}$  to  $\text{IF}_{\text{confined}}^{\text{heme}}$  entails centered movements of TM3<sup>C</sup> and TM4<sup>D</sup>. This seals the cytoplasmic gate from solvent access and results in a pseudo-symmetric heterodimer conformation (Extended Data Fig. 8, Supplementary Fig. 16 and Supplementary Video 10).

We obtained two outward-open models ( $\text{Occ}_{\text{confined}}^{\text{heme}}$  and  $\text{OF}_{\text{confined}}^{\text{heme}}$ ) by performing steered MD simulations on the two periplasmic halves of CydDC. Having generated initial models, we checked the stability and the degree of opening after 300 ns of unrestrained simulations (Supplementary Fig. 16). Our outward-facing models suggest that heme might be released in a sequential process. First, the periplasmic gate formed by all 12 TMs is opened via separation of two lobes composed of TMs 1–2 of CydC and 4–6 of CydD, and of TMs 1–2 of CydD and 4–6 of CydC ( $\text{OF}^{\text{apo}}$ ) (Extended Data Fig. 9 and Supplementary Video 11). During periplasmic gate opening we found that the overall interaction of heme with the residues in the binding site remained unchanged. Even when we performed steered MD simulations on the  $\text{OF}_{\text{confined}}^{\text{heme}}$  conformation with heme not covalently bound to the coordinating histidines, the overall interaction of heme with the residues in the binding site remained unchanged. Accordingly, we conclude that substrate release is initiated by retraction of H312 of TM6<sup>D</sup> and H85 of TM2<sup>C</sup> (Extended Data Figs. 8 and 9 and Supplementary Video 12). These events most likely change the local affinity and trigger the release toward the periplasmic side of the membrane. However, the release process time scale is most likely much longer than our submicrosecond simulations, as we do not see any release event in our simulations. The postrelease  $\text{Occ}_{\text{confined}}^{\text{heme}}$  conformation features a narrower periplasmic gate than  $\text{OF}^{\text{apo}}$  during the MD simulations (Supplementary Fig. 16). With the complete closing of the periplasmic gate, the transporter adopts its prehydrolysis  $\text{OF}_{\text{confined}}^{\text{heme}}$  conformation as observed in the cryo-EM structures of CydDC<sup>E500Q</sup> (Fig. 2c and Extended Data Fig. 9). In this state, TM6<sup>D</sup> and TM2<sup>C</sup> already adopt the  $\text{Occ}_{\text{return}}^{\text{apo}}$  conformation, which would ensure rapid binding of another heme molecule after ATP hydrolysis and lateral opening of the substrate entry gate (Extended Data Figs. 8 and 9 and Supplementary Video 13).

## Discussion

The molecular basis of CydDC function has been contested for 30 years. The results from various in vitro and in vivo studies led to conflicting conclusions about its role in bacterial physiology, and its function as a heme transporter was previously ruled out<sup>21,26,27</sup>. In this study, we provide evidence that translocation of protoheme (heme *b*) from the cytoplasmic space to the periplasm is indeed a primary function of this ABC transporter, which is essential for the functional maturation of cytochrome *bd* (Supplementary Fig. 17).

Based on our multi-layered approach, we suggest a model for the transport cycle that integrates the results of the complementary methods used in this study (Extended Data Fig. 10 and Supplementary Videos 14 and 15). We assign the ATP-bound  $\text{IF}_{\text{asym}}^{\text{apo}}$  state as the starting conformation. We biochemically confirmed that NBD<sup>C</sup> is essential for the ATPase activity of CydDC (Fig. 1d). In line with this, our structural data indicate that hydrolysis of ATP at this site is required for a mechanochemically induced return to the substrate-free  $\text{Occ}_{\text{return}}^{\text{apo}}$  state (Figs. 3a and 5c and Supplementary Fig. 11). By this rationale, we assign the densities at NBS<sup>C</sup> of this posthydrolysis state obtained from the turnover dataset of CydDC to ADP and Pi (Fig. 5c and Extended Data Fig. 7a). We further conclude that heme binding to the TMH domain

and ATP to NBD<sup>C</sup> occurs sequentially rather than simultaneously, given that the binding and occlusion of heme ( $\text{IF}_{\text{asym}}^{\text{apo}} > \text{IF}_{\text{bound}}^{\text{heme}} > \text{IF}_{\text{coordinated}}^{\text{heme}}$ ) is needed to induce dissociation of the distal NBD–NBD interaction, causing NBS<sup>C</sup> to collapse and release ADP and Pi (Figs. 3–5 and Supplementary Videos 7–9). This latter observation supports our assignment of ADP and Pi in the density maps of  $\text{IF}_{\text{confined}}^{\text{heme}}$  and  $\text{IF}_{\text{bound}}^{\text{heme}}$  obtained under active turnover conditions of wild-type CydDC with regard to the sequence of conformation changes making up the overall transport cycle. Given the fact that heme binding itself is not sufficient to drive the conformational transition toward the return state conformation but merely results in enrichment of the  $\text{IF}_{\text{asym}}^{\text{apo}}$  population, we conclude that binding of ATP to NBS<sup>C</sup> is essential for the transition to the fully occluded  $\text{IF}_{\text{confined}}^{\text{heme}}$  state. In our MD simulations, this state is followed by the opening of the extracellular gate, the retraction of TM6<sup>C</sup>, including the axial heme ligand H312<sup>D</sup>, to adopt the inward-facing conformation of this helix and the collapsing of the heme-binding site ( $\text{Occ}_{\text{confined}}^{\text{heme}}$ ) (Extended Data Figs. 8 and 9 and Supplementary Videos 10–13). After release of the heme to the periplasmic space, the extracellular gate closes again, reverting back to the  $\text{OF}^{\text{apo}}$  conformation. This is in agreement with the observation that under turnover conditions of CydDC<sup>E500Q</sup> in which heme and ATP are present, we exclusively captured the occluded return state conformation. Notably, this is the sole analyzed condition, that does not result in a heme-bound conformation of CydDC. A lack of ATP hydrolysis activity of the CydDC<sup>E500Q</sup> variant traps the transporter in the postsubstrate-release state suggesting that the key role of ATP hydrolysis is to convert CydDC to the  $\text{Occ}_{\text{return}}^{\text{apo}}$ , as observed in the turnover dataset of CydDC<sup>wt</sup>.

The transitional cycle of asymmetrical, symmetry-approaching and pseudo-symmetrical conformations during heme transport is unique to CydDC and highlights the mechanistic possibilities for the specialized substrate transport facilitated by heterodimeric ABC transporters and their diverse conformational space (Supplementary Fig. 18).

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41589-023-01314-5>.

## References

- Li, Z. *Heme Biology: The Secret Life of Heme in Regulating Diverse Biological Processes* (World Scientific Publishing Company, 2011).
- Li, Z. *Heme Biology: Heme Acts As A Versatile Signaling Molecule Regulating Diverse Biological Processes* 2nd edn (World Scientific Publishing Company, 2020).
- Lindley, P. F. Iron in biology: a structural viewpoint. *Rep. Prog. Phys.* **59**, 867–933 (1996).
- Ganz, T. & Nemeth, E. Iron homeostasis in host defence and inflammation. *Nat. Rev. Immunol.* **15**, 500–510 (2015).
- Andrews, N. C. Iron metabolism: iron deficiency and iron overload. *Annu. Rev. Genom. Hum. Genet.* **1**, 75–98 (2000).
- Andrews, S. C., Robinson, A. K. & Rodriguez-Quinones, F. Bacterial iron homeostasis. *FEMS Microbiol. Rev.* **27**, 215–237 (2003).
- Lienemann, M. Molecular mechanisms of electron transfer employed by native proteins and biological-inorganic hybrid systems. *Comput. Struct. Biotechnol. J.* **19**, 206–213 (2020).
- Safarian, S. et al. Active site rearrangement and structural divergence in prokaryotic respiratory oxidases. *Science* **366**, 100–104 (2019).
- Safarian, S. et al. The cryo-EM structure of the *bd* oxidase from *M. tuberculosis* reveals a unique structural framework and enables rational drug design to combat TB. *Nat. Commun.* **12**, 5236 (2021).

10. Kolbe, F. et al. Cryo-EM structures of intermediates suggest an alternative catalytic reaction cycle for cytochrome c oxidase. *Nat. Commun.* **12**, 6903 (2021).
11. Buschmann, S. et al. The structure of *cbb3* cytochrome oxidase provides insights into proton pumping. *Science* **329**, 327–330 (2010).
12. Abramson, J. et al. The structure of the ubiquinol oxidase from *Escherichia coli* and its ubiquinone binding site. *Nat. Struct. Biol.* **7**, 910–917 (2000).
13. Soulimane, T. et al. Structure and mechanism of the aberrant *ba3*-cytochrome c oxidase from *Thermus thermophilus*. *EMBO J.* **19**, 1766–1776 (2000).
14. Grund, T. N. et al. Mechanistic and structural diversity between cytochrome *bd* isoforms of *Escherichia coli*. *Proc. Natl Acad. Sci. USA* **118**, e2114013118 (2021).
15. Wang, W. et al. Cryo-EM structure of mycobacterial cytochrome *bd* reveals two oxygen access channels. *Nat. Commun.* **12**, 4621 (2021).
16. Mascolo, L. & Bald, D. Cytochrome *bd* in *Mycobacterium tuberculosis*: a respiratory chain protein involved in the defense against antibacterials. *Prog. Biophys. Mol. Biol.* **152**, 55–63 (2020).
17. Bald, D., Vilellas, C., Lu, P. & Koul, A. Targeting energy metabolism in *Mycobacterium tuberculosis*, a new paradigm in antimycobacterial drug discovery. *MBio* **8**, 159 (2017).
18. Holyoake, L. V., Poole, R. K. & Shepherd, M. The CydDC family of transporters and their roles in oxidase assembly and homeostasis. *Adv. Microb. Physiol.* **66**, 1–53 (2015).
19. Poole, R. K., Gibson, F. & Wu, G. H. The *Cydc* gene product, component of a heterodimeric ABC transporter, is required for assembly of periplasmic cytochrome c and of cytochrome *bd* in *Escherichia coli*. *FEMS Microbiol. Lett.* **117**, 217–224 (1994).
20. Goldman, B. S., Gabbert, K. K. & Kranz, R. G. Use of heme reporters for studies of cytochrome biosynthesis and heme transport. *J. Bacteriol.* **178**, 6338–6347 (1996).
21. Georgiou, C. D., Fang, H. & Gennis, R. B. Identification of the *cydC* locus required for expression of the functional form of the cytochrome *d* terminal oxidase complex in *Escherichia coli*. *J. Bacteriol.* **169**, 2107–2112 (1987).
22. Bebbington, K. J. & Williams, H. D. Investigation of the role of the *cydD* gene product in production of a functional cytochrome *d* oxidase in *Escherichia coli*. *FEMS Microbiol. Lett.* **112**, 19–24 (1993).
23. Shepherd, M. The CydDC ABC transporter of *Escherichia coli*: new roles for a reductant efflux pump. *Biochem. Soc. T.* **43**, 908–912 (2015).
24. Poole, R. K. et al. Cytochrome *bd* biosynthesis in *Escherichia coli*: the sequences of the *cydC* and *cydD* genes suggest that they encode the components of an ABC membrane transporter. *Mol. Microbiol.* **10**, 421–430 (1993).
25. Pittman, M. S., Robinson, H. C. & Poole, R. K. A bacterial glutathione transporter (*Escherichia coli* CydDC) exports reductant to the periplasm. *J. Biol. Chem.* **280**, 32254–32261 (2005).
26. Pittman, M. S. et al. Cysteine is exported from the *Escherichia coli* cytoplasm by CydDC, an ATP-binding cassette-type transporter required for cytochrome assembly. *J. Biol. Chem.* **277**, 49841–49849 (2002).
27. Goldman, B. S., Gabbert, K. K. & Kranz, R. G. The temperature-sensitive growth and survival phenotypes of *Escherichia coli* *cydDC* and *cydAB* strains are due to deficiencies in cytochrome *bd* and are corrected by exogenous catalase and reducing agents. *J. Bacteriol.* **178**, 6348–6351 (1996).
28. Holyoake, L. V. et al. CydDC-mediated reductant export in *Escherichia coli* controls the transcriptional wiring of energy metabolism and combats nitrosative stress. *Biochem. J.* **473**, 693–701 (2016).
29. Yamashita, M. et al. Structure and function of the bacterial heterodimeric ABC transporter CydDC: stimulation of ATPase activity by thiol and heme compounds. *J. Biol. Chem.* **289**, 23177–23188 (2014).
30. Mironov, A. et al. CydDC functions as a cytoplasmic cystine reductase to sensitize *Escherichia coli* to oxidative stress and aminoglycosides. *Proc. Natl Acad. Sci. USA* **117**, 23565–23570 (2020).
31. Goojani, H. G. et al. The carboxy-terminal insert in the Q-loop is needed for functionality of *Escherichia coli* cytochrome *bd*-I. *Biochim. Biophys. Acta - Bioenerg.* **148175**, 2020 (1861).
32. Arutyunyan, A. M., Sakamoto, J., Inadome, M., Kabashima, Y. & Borisov, V. B. Optical and magneto-optical activity of cytochrome *bd* from *Geobacillus thermodenitrificans*. *Biochim. Biophys. Acta - Bioenerg.* **1817**, 2087–2094 (2012).
33. Grauel, A. et al. Structure of *Escherichia coli* cytochrome *bd*-II type oxidase with bound aurachin D. *Nat. Commun.* **12**, 6498 (2021).
34. Theßeling, A. et al. Homologous *bd* oxidases share the same architecture but differ in mechanism. *Nat. Commun.* **10**, 5138 (2019).
35. Cruz-Ramos, H., Cook, G. M., Wu, G., Cleeter, M. W. & Poole, R. K. Membrane topology and mutational analysis of *Escherichia coli* CydDC, an ABC-type cysteine exporter required for cytochrome assembly. *Microbiology* **150**, 3415–3427 (2004).
36. Mepin, R. et al. Release of extracellular ATP by bacteria during growth. *BMC Microbiol.* **13**, 301 (2013).
37. Nobles, C. L., Clark, J. R., Green, S. I. & Maresco, A. W. A dual component heme biosensor that integrates heme transport and synthesis in bacteria. *J. Microbiol. Methods* **118**, 7–17 (2015).
38. Stockner, T., Gradisch, R. & Schmitt, L. The role of the degenerate nucleotide binding site in type I ABC exporters. *FEBS Lett.* **594**, 3815–3838 (2020).
39. Thomas, C. et al. Structural and functional diversity calls for a new classification of ABC transporters. *FEBS Lett.* **594**, 3767–3775 (2020).
40. Hohl, M., Briand, C., Grütter, M. G. & Seeger, M. A. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation. *Nat. Struct. Mol. Biol.* **25**, 395–402 (2012).
41. Noell, A. et al. Crystal structure and mechanistic basis of a functional homolog of the antigen transporter TAP. *Proc. Natl Acad. Sci. USA* **114**, E438–E447 (2017).
42. Oswald, C., Holland, I. B. & Schmitt, L. The motor domains of ABC-transporters. *Naunyn Schmiedebergs Arch. Pharmacol.* **372**, 385–399 (2006).
43. Light, W. R. & Olson, J. S. Transmembrane movement of heme. *J. Biol. Chem.* **265**, 15623–15631 (1990).
44. Light, W. R. & Olson, J. S. The effects of lipid composition on the rate and extent of heme binding to membranes. *J. Biol. Chem.* **265**, 15632–15637 (1990).
45. Olsen, J. A., Alam, A., Kowal, J., Stieger, B. & Locher, K. P. Structure of the human lipid exporter ABCB4 in a lipid environment. *Nat. Struct. Mol. Biol.* **27**, 62–70 (2020).
46. Mi, W. et al. Structural basis of MsbA-mediated lipopolysaccharide transport. *Nature* **549**, 233–237 (2017).
47. Kim, Y. & Chen, J. Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. *Science* **359**, 915–919 (2018).
48. Lambert, E., Mehdipour, A. R., Schmidt, A., Hummer, G. & Perez, C. Evidence for a trap-and-flip mechanism in a proton-dependent lipid transporter. *Nat. Commun.* **13**, 1022 (2022).
49. Zakrzewska, S. et al. Inward-facing conformation of a multidrug resistance MATE family transporter. *Proc. Natl Acad. Sci. USA* **116**, 12275–12284 (2019).

50. Hofmann, S. et al. Conformation space of a heterodimeric ABC exporter under turnover conditions. *Nature* **571**, 580–583 (2019).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the

source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

## Methods

### Production of CydDC from *E. coli*

CydDC from *E. coli* was produced in *E. coli* BL21-pLysS (DE3) cells transformed with a pTTQ18 plasmid carrying structural genes of the CydDC heterodimer (*cydD* + *cydC*) and encoding a C-terminal hexahistidine modification at CydC for downstream IMAC purification (*pcydDC*)<sup>29</sup>. Mutant variants CydDC<sup>E500Q</sup> (*pE500Q*), CydD<sup>E511Q</sup>C (*pE511Q*) and CydD-C<sup>H85A</sup> (*pH85A*) were produced analogously. Further details are found in sequence data provided as Supplementary Information (Supplementary Tables 2 and 3).

For an initial preculture, a volume of 0.1 ml of 50% glycerol stock of each respective strain was added to 200 ml of M9-Carb (50 µg ml<sup>-1</sup> carbenicillin) growth medium. Cells were incubated at 37 °C while shaking (185 rpm) for 16–20 h. The production culture was started by inoculating 2 l of M9-Carb (50 µg ml<sup>-1</sup> carbenicillin) growth medium with the preculture adjusted to a starting optical density (OD<sub>600</sub>) of 0.1. Cells were grown while shaking (185 rpm) at 37 °C until an OD<sub>600</sub> of 0.6 before recombinant production was induced by addition of isopropyl-β-D-thiogalactoside at a final concentration of 0.6 mM. Gene expression was carried out at 30 °C for 16–18 h. After collection, cells were disrupted using a French-press cell disruptor (Thermo Fisher Scientific) via double pass at a pressure of 700–1,000 psi. The cell lysate was centrifuged at 5,000g at 4 °C for 30 min. Subsequently, the low-velocity supernatant was centrifuged at 220,000g at 4 °C for 90 min. Pelleted membranes were resuspended and stored at a protein concentration of 10 mg ml<sup>-1</sup> in a storage buffer containing 50 mM Tris-HCl (pH 7.4) and 100 mM KCl.

### Purification of CydDC from *E. coli*

Isolated membranes were solubilized with 1% dodecyl-β-D-maltoside (DDM) in a mass ratio of 1 mg detergent per 5 mg of membrane protein for 60 min at 4 °C. CydDC was purified via His<sub>6</sub>-tag affinity chromatography using a Talon (Co-IMAC) affinity matrix (Takara Bio Inc.). For column conditioning and washing step I (10 column volumes (CV)) a buffer containing 50 mM Tris-HCl (pH 8), 500 mM KCl, 10% (v/v) glycerol, 20 mM imidazole, and 0.02% DDM was used. For samples intended to be used for cryo-EM studies, the resin was additionally washed with 10 CV of washing buffer II containing 50 mM Tris-HCl (pH 8), 500 mM KCl, 10% (v/v) glycerol, 20 mM imidazole and 0.05% lauryl maltose neopentyl glycol (LMNG) to perform detergent exchange from DDM to LMNG. For step elution (5 × 1 CV), buffers I and II were adjusted to a final imidazole concentration of 300 mM, respectively. For sample polishing, size-exclusion chromatography was performed using a Superdex 200 10/300 Increase column. The size-exclusion chromatography running buffer contained 20 mM MES (pH 6), 50 mM KCl and either 0.02% DDM or 0.001% LMNG. All steps of the purification process were carried out at 4 °C.

### Growth-complementation studies

The bacterial growth assays were carried out as described previously<sup>31</sup>. Precultures of *E. coli* MB43 and MB43Δ*cydDC* (transformed with empty pET17 control vector or with plasmids encoding one of the cytochrome *bd* variants and/or CydDC) were incubated in Luria Bertani (LB) medium with 100 µg ml<sup>-1</sup> ampicillin overnight at 37 °C while shaking at 200 rpm. Bacteria were then diluted to OD<sub>600</sub> of 0.01 with 200 µl of LB medium containing 100 µg ml<sup>-1</sup> ampicillin and each sample was subsequently distributed over eight wells (technical replicates) of a 96-well microtiter plate. OD<sub>600</sub> was measured every 5 min at 37 °C for 20 h (shaking at 200 rpm) in a SpectraMax Plus 384 Microplate reader (Molecular Devices).

### ATP hydrolysis assays

**Malachite green phosphate assay.** ATPase activity of CydDC was determined colorimetrically as described previously<sup>51</sup>. In brief, measurements were performed at a final concentration of 50 nM CydDC

(in DDM) in a volume of 25 µl and carried out for 5 min at 37 °C. Reactions were stopped by adding 175 µl of ice cold stopping buffer (20 mM H<sub>2</sub>SO<sub>4</sub>) and stored on ice. For detection, 175 µl of a stopped reaction sample was transferred into a 96-well microtiter plate and incubated for 8 min with 50 µl of malachite green solution (2.7 mM malachite green chloride, 0.17% Tween, 1.5% Na<sub>2</sub>MoO<sub>4</sub>) at room temperature. The absorbance change at 620 nm was measured by a SpectraMax M2 Microplate Reader (Molecular Devices). For heme titration experiments a constant ATP concentration of 1 mM was used. ATP titration experiments were performed at a constant heme concentration of 0.3 µM. Substrate screening experiments were performed using following final concentrations of the respective reaction components: ATP (1 mM), ferrous heme (0.5 µM), ferric heme (0.5 µM), protoporphyrin IX (0.5 µM), FeCl<sub>3</sub> (0.5 µM), GSH (1 mM), glutathione disulfide (1 mM), L-Cys (0.5 mM), cystine (1 µM), orthovanadate (1 mM) and AMP-PNP (1 mM). All measurements were performed in a reaction buffer containing 20 mM Tris-HCl (pH 7.0), 50 mM KCl, 0.02% DDM and 3 mM MgCl<sub>2</sub>. Samples without substrate were used as negative control and subtracted as background. All data are presented as mean ± s.d. (*n* = 3). Statistical significance was analyzed via paired two-tailed Student's *t*-tests using the GraphPad *t*-Test calculator (<https://www.graphpad.com/quickcalcs/ttest1/>).

**Enzyme-coupled ATPase assay.** The pyruvate kinase and lactate dehydrogenase coupled ATP hydrolysis assay was performed as described previously<sup>52</sup>. In brief, a volume of 100 µl of activity buffer (20 mM Tris-HCl (pH 7.0), 50 mM KCl, 4 mM MgCl<sub>2</sub>, 350 µM PEP, 350 µM ATP, 350 µM NADH, 0.02% DDM) was mixed with 2.5 µl of pyruvate kinase and lactate dehydrogenase enzyme solution (Sigma Aldrich, P0294) and incubated for 5 min at 37 °C in a 96-well microtiter plate. Subsequently, putative substrate candidates and CydDC (0.6 µM final concentration) were added. Kinetic turnover was monitored at 340 nm for 45 min every 10 s using the SpectraMax M2 Microplate Reader (Molecular Devices). All data are presented as mean ± s.d. (*n* = 3). Statistical significance was analyzed via paired two-tailed Student's *t*-tests using the GraphPad *t*-Test calculator (<https://www.graphpad.com/quickcalcs/ttest1/>).

### Determination of thermal stability by microscale thermophoresis

Thermal stabilities of purified CydDC variants were investigated with a Prometheus NT.48 instrument (Nanotemper). Excitation at 280 nm (20 nm bandwidth) was set to a power of 10% yielding emission intensities of 6,000 to 25,000 at 333–380 nm. A temperature ramp of 1 °C min<sup>-1</sup> between 20 and 95 °C was applied in all experiments. Measurements were performed at 2 µM CydDC concentration. Heme was added in equimolar concentrations to CydDC. Unfolding transitions were monitored from changes in the emission of tryptophan and tyrosine fluorescence at 350 and 330 nm, respectively. Melting temperatures were determined at the inflection points (free energy change Δ*G* is equal to zero) from the raw data (measured in triplicates) after baseline correction and normalization.

### Cryo-EM sample preparation

To collect cryo-EM data of CydDC in different sample conditions, different combinations of CydDC variants, nucleotides, inhibitors and putative substrate molecules were prepared. See Fig. 2c and Supplementary Fig. 7 for details of specific sample conditions. For all nonturnover datasets, the protein concentration was adjusted to approximately 1.5 mg ml<sup>-1</sup> before other components were added. Heme loading was performed before sample vitrification. Heme was adjusted to a final concentration of 17 µM in all heme containing samples. Nucleotides and inhibitors (ADP, AMP-PNP and ATP-orthovanadate) were used at a final concentration of 1 mM (+2 mM MgCl<sub>2</sub>). Putative substrate molecules were screened at final concentrations of 1 mM. Owing to poor

aqueous solubility, cystine was adjusted to the highest possible final concentration of 0.2 mM. Samples were incubated for 2 min at room temperature before plunge freezing.

For preparation of turnover samples, the protein concentration was adjusted to 3 mg ml<sup>-1</sup>. Subsequently, heme was added at a final concentration of 34 μM. The sample was then mixed with a freshly prepared ATPase buffer (20 mM MES (pH 6), 50 mM KCl, 0.001% LMNG, 10 mM ATP and 20 mM MgCl<sub>2</sub>) in a ratio of 1:1, incubated for 30 s at 37 °C and immediately subjected to plunge freezing. Identical plunge freezing conditions were applied for all samples: Quantifoil R1.2/1.3 copper grids (mesh 300) were washed in chloroform and subsequently glow discharged with a PELCO easiGlow device at 15 mA for 90 s. A volume of 4 μl of sample was applied to a grid and blotting was performed for 4 s at 4 °C, 100% humidity with nominal blot force 20 immediately before freezing in liquid ethane, using a Vitrobot Mark IV device (Thermo Scientific).

### Cryo-EM image recording

For each cryo-EM sample, a dataset was recorded in Energy-Filtered Transmission Electron Microscopy (EF-TEM) mode using either a Titan Krios G2 or a Krios G3i microscope (Thermo Scientific), both operated at 300 kV. Electron-optical alignments were adjusted with EPU 2.9–2.11 (Thermo Scientific). Images were recorded using automation strategies of EPU 2.9–2.11 in electron counting mode with either a Gatan K2 (installed on Krios G2) or a Gatan K3 (installed on Krios G3i) direct electron detector at a nominal magnification of 105,000, corresponding to a calibrated pixel size of 0.831 and 0.837 Å, respectively. Dose fractionated movies (40 frames) were recorded at an electron flux of approximately 15 e<sup>-</sup> pixel<sup>-1</sup> s<sup>-1</sup> for 2 s, corresponding to a total dose of roughly 40 e<sup>-</sup>/Å<sup>2</sup>. Images were recorded between -1.1 and -2.1 μm nominal defocus. CryoSPARC Live v.3.0 was used for real-time cryo-EM data quality assessment.

### Cryo-EM image processing

For each acquired dataset, the same cryo-EM image processing approach was applied: MotionCor2 was used to correct for beam-induced motion and to generate dose-weighted images<sup>53</sup>. Gctf was used to determine the contrast transfer function parameters and perform correction steps<sup>54</sup>. Images with estimated poor resolution (<4 Å) and severe astigmatism (> 400 Å) were removed at this step. Particles were picked by crYOLO and used for all further processing steps<sup>55</sup>. Two-dimensional classification, initial model generation, three-dimensional classification, contrast transfer function refinement, Bayesian polishing, three-dimensional sorting and final map reconstructions were performed using RELION-3.1 (ref. 56). Fourier shell correlation curves were generated in RELION-3.1. Local-resolution estimation was performed in RELION-3.1 for all final maps. A schematic overview of our processing workflow, and a summary of map qualities are shown in Supplementary Figs. 4–7 and 9.

### Model building and geometry refinement

The first atomic model of CydDC was built de novo into the EM density map of the IF<sub>asym</sub><sup>apo</sup> state in Coot (v.0.8). After manual backbone tracing and docking of side chains in the respective map densities real-space refinement in Phenix was performed (v.1.14 and 1.18)<sup>57</sup>. Refinement results were manually inspected and corrected if required. This model was used as a template to build all subsequent atomic models. In total, 17 models were built, refined, inspected and corrected (Supplementary Fig. 8). The finalized models were validated by MolProbity implemented in Phenix. Map-to-model cross validation was performed in Phenix (v.1.14 and 1.18). Fourier shell correlation<sub>0.5</sub> was used as cutoff to define resolution. A summary of model parameters and the corresponding cryo-EM map statistics is found in Supplementary Table 1. The finalized models were visualized using ChimeraX. Highest resolution models of IF<sub>as isolated</sub><sup>apo</sup>, IF<sub>as isolated</sub><sup>apo</sup>, IF<sub>asym</sub><sup>apo</sup>, IF<sub>bound</sub><sup>heme</sup>, IF<sub>coordinated</sub><sup>heme</sup> and IF<sub>confined</sub><sup>heme</sup> states were used as starting structures for MD simulations.

### Tunnels and interior cavities

Tunnels and cavities were mapped with MOLE 2.5 with a bottleneck radius of 1.2 Å, bottleneck tolerance 3 Å, origin radius 5 Å, surface radius 10 Å, probe radius 5 Å and an interior threshold of 1.1 Å.

### Structural alignments

The overall folds of the CydDC subunits CydC and CydD were compared with each other using the structural alignment program TM-align. Subunits, individual transmembrane regions and NBDs were aligned and respective Cα r.m.s.d. values were calculated.

### MD simulations

The CydDC structures were placed in a heterogenous bilayer composed of POPE (70%), POPG (25%) and CL (5%) using CHARMM-GUI<sup>58</sup>. All systems were hydrated with 150 mM NaCl electrolyte. The all-atom CHARMM36m force field was used for lipids, ions, cofactors and protein with TIP3P water. MD trajectories were analyzed using Visual Molecular Dynamics and MDAAnalysis.

All simulations were performed using GROMACS v.2021.2 (ref. 59). Starting systems were energy minimized for 5,000 steepest descent steps and equilibrated initially for 500 ps of MD in a canonical (NVT) ensemble and later for 7.5 ns in an isothermal-isobaric (NPT) ensemble under periodic boundary conditions. During equilibration, the restraints on the positions of nonhydrogen protein atoms of initially 4,000 kJ mol<sup>-1</sup> nm<sup>-2</sup> were gradually released. Particle-mesh Ewald summation with cubic interpolation and a 0.12-nm grid spacing was used to treat long-range electrostatic interactions. The time step was initially 1 fs, and was increased to 2 fs during the NPT equilibration. The LINCS algorithm was used to fix all bond lengths. Constant temperature was established with a Berendsen thermostat, combined with a coupling constant of 1.0 ps. A semi-isotropic Berendsen barostat was used to maintain a pressure of 1 bar. During production runs, the Berendsen thermostat and barostat were replaced by a Nosé–Hoover thermostat and a Parrinello–Rahman barostat. All simulations were performed at 310 K. Analysis was carried out on unconstrained simulations. Simulations with liganded and unliganded heme were performed for 450 ns for each of Occ<sub>return</sub><sup>apo</sup>, IF<sub>bound</sub><sup>heme</sup> and IF<sub>coordinated</sub><sup>heme</sup> states.

For heme entry simulations a heterogenous bilayer composed of POPE (70%), POPG (25%) and CL (5%) was built using CHARMM-GUI. The system was hydrated with 150 mM NaCl electrolyte. After 7 ns of equilibration, a production run was performed for 100 ns. Then, a heme molecule (ferrous state) was placed 1 nm away from the membrane. Ten separate MD simulations were initiated with independent initial velocities drawn according to the Boltzmann distribution of the targeted temperature. Each replicate was run for additional 100 ns. In seven out of the ten simulations, the heme molecule had partitioned into the membrane bilayer at the end of 100 ns simulation. The IF<sub>confined</sub><sup>heme</sup> CydDC structure was placed in a heterogenous bilayer composed of POPE (70%), POPG (25%) and CL (5%) using CHARMM-GUI. Then, a heme molecule was placed near the lateral opening between TM4<sup>D</sup> and TM6<sup>D</sup> in five different positions. After equilibration, a simulation of 100 ns duration was performed for each setup.

We modeled the IF<sub>as isolated</sub><sup>apo</sup> state, which represents the heme-loaded conformation of CydDC on ATP binding, with tightly interlocked NBDs. To obtain this conformation, we first ran an MD simulation for the fully occluded state of CydDC without heme (Occ<sub>confined</sub><sup>heme</sup>) for 400 ns to get an equilibrated structure in the membrane bilayer. Then, the end structure of this simulation was aligned with the Occ<sub>return</sub><sup>apo</sup> conformation and a virtual heme molecule was placed in the approximate position of the binding site taken from the aligned IF<sub>confined</sub><sup>heme</sup> conformation. In the next step, three independent simulations were carried out to generate the IF<sub>confined</sub><sup>heme</sup> conformation by gradually turning on the interactions of the virtual heme with the protein and the rest of the system. Increasing a lambda parameter scaling these interactions slowly from 0 to 1, over 1 ns with a 0.5 fs time step, results in the insertion of heme by slow

growth. This method allows for smooth adaptation of amino acids in the binding site to the presence of heme. Extra position restraints were added to the C-alpha atoms of the NBDs to stabilize the conformation of protein during the slow-growth process. After the slow-growth heme insertion, we added the axial ligation bonds between heme and H85<sup>C</sup> and H312<sup>D</sup> and energy minimized the system. Then, we performed 300 ns of simulation. Structural stability during simulations was checked by r.m.s.d. evolution and conformation dynamics.

To obtain structural models of the two elusive outward-facing ( $\text{Occ}_{\text{confined}}^{\text{heme}}$  and  $\text{OF}_{\text{confined}}^{\text{heme}}$ ) states, we performed steered MD simulations starting from  $\text{OF}_{\text{apo}}^{\text{apo}}$  and  $\text{Occ}_{\text{confined}}^{\text{heme}}$ , respectively. A bias was applied on the distance between the center of mass of the two periplasmic halves of CydC. The periplasmic halves are defined as (1) TM1–2 of CydC and TM3–6 of CydD and (2) TM1–2 of CydD and TM3–6 of CydC. The initial value of the distance was 19 Å and the target value was 28 Å (based on the outward-open structure of TmrAB Protein Data Bank ID 6RAJ). The steered MD was performed in PLUMED-patched Gromacs with an approximate velocity of 0.01 nm ns<sup>-1</sup>. The steered MD simulation was performed for 100 ns. After the simulation and full opening of the periplasmic side, we ran a further 50 ns of restrained simulation that allowed the lipid molecules around the periplasmic site to equilibrate around the new conformation. Finally, we checked the stability and the degree of opening after 300 ns of unrestrained simulations (Supplementary Fig. 16).

A list of all the simulations performed in this study is presented in Supplementary Table 4 in the Supplementary Information with their corresponding descriptions and time lengths.

### Preparation of membrane fractions for heme spectra and oxygen consumption assays

Membrane fractions were isolated as described previously<sup>60</sup>. In brief, *E. coli* strains were grown in 800 ml of LB medium (2-l baffled flasks) from a starting OD<sub>600</sub> of 0.01 until the late exponential phase. After washing with phosphate buffer saline, batches of cells (5 g) were resuspended in a buffer composed of 50 mM MOPS (pH 7), 100 mM NaCl and complete protease inhibitor (Roche) in a ratio of 5:1. Cells were disrupted using a Stansted homogenizer at 1.2 kbar. Cell debris was removed by centrifugation at 9,500g for 20 min at 4 °C. Membrane fractions were collected by ultracentrifugation at 250,000g for 75 min at 4 °C. Membranes were resuspended in the above buffer containing 0.025% DDM, and used for downstream oxygen consumption activity assays and spectroscopic analysis of heme cofactors.

### UV-vis absorption spectroscopy for heme identification

The heme composition of membrane fractions was analyzed by reduced-minus oxidized UV-vis spectra based on Goojani et al.<sup>31</sup>. Membrane fractions were diluted to a protein concentration of 2.6 mg ml<sup>-1</sup> in a buffer composed of 10 mM Tris (pH 7.4) and 16 mM sodium cholate. Samples were first oxidized with 100 μM potassium ferricyanide and a spectrum was recorded at room temperature using a Varian Cary 50 UV-vis Spectrophotometer. Subsequently, a few grains of solid sodium hydrosulfite were dissolved in the sample to measure the spectrum in the fully reduced state. The difference spectrum (reduced–oxidized) was calculated using OriginLab Pro v.9.5 (Additive GmbH).

### Oxygen consumption measurements

The oxygen consumption activity of membrane fractions was measured using a Clark-type electrode based on Goojani et al.<sup>31</sup>. The membrane fractions were adjusted to a concentration of 0.01–0.03 mg ml<sup>-1</sup> using a buffer composed of 50 mM MOPS (pH 7.0), 100 mM NaCl and 0.025% DDM. Subsequently, the membrane fractions were preincubated with either aurachin D (final concentration 400 nM) or with dimethylsulfoxide as control for 3 min in the electrode chamber. Ubiquinone-1 and dithiothreitol (DTT) were preincubated separately for 3 min and then injected into the electrode chamber to start the reaction (final

concentration of 200 μM ubiquinone-1 and 10 mM DTT). The reaction rate was determined for the period between 90 and 150 s after addition of the substrate mixture. Statistical significance was analyzed via paired two-tailed Student's *t*-tests using the GraphPad *t*-test calculator (<https://www.graphpad.com/quickcalcs/ttest1/>).

### Multiple sequence alignments

Multiple sequence alignments of CydD and CydC from *E. coli* (strain K12), *Mycobacterium tuberculosis* (strain ATCC 25618/H37Rv), *Mycobacterium smegmatis* MC2-155, *Mycobacterium bovis* (strain ATCC BAA-935/AF2122/97), *Corynebacterium glutamicum*, *Brucella abortus* biovar, *Shewanella violacea* (strain JCM10179/CIP 106290/LMG 19151/DSS12), *Geobacillus stearothermophilus* and *Klebsiella pneumoniae* were performed using Clustal Omega and visualized using Jalview v.2.11.2.0.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Cryo-EM maps are deposited at the Electron Microscopy Data Bank under accession numbers EMD-14636, EMD-14638, EMD-14639, EMD-14640, EMD-14641, EMD-14642, EMD-14643, EMD-14644, EMD-14645, EMD-14646, EMD-14647, EMD-14649, EMD-14652, EMD-14653, EMD-14654, EMD-14655, EMD-14656, EMD-14657, EMD-14659, EMD-14660, EMD-14662, EMD-14663, EMD-14665, EMD-14667, EMD-14668, EMD-14669, EMD-14670, EMD-14671, EMD-14672, EMD-14673, EMD-14674, EMD-14675, EMD-14676, EMD-14684, EMD-14689, EMD-15264 and EMD-15265. Atomic models of CydC have been deposited to the Protein Data Bank under accession numbers: 7ZD5, 7ZDA, 7ZDB, 7ZDC, 7ZDE, 7ZDF, 7ZDG, 7ZDK, 7ZDL, 7ZDR, 7ZDS, 7ZDT, 7ZDU, 7ZDV, 7ZDW, 7ZES and 7ZEC. All other data are presented in the main text or Supplementary Information. Source data are provided with this paper.

### References

- Morbach, S., Tebbe, S. & Schneider, E. The ATP-binding cassette (ABC) transporter for maltose/maltodextrins of *Salmonella typhimurium*. Characterization of the ATPase activity associated with the purified MalK subunit. *J. Biol. Chem.* **268**, 18617–18621 (1993).
- Yun, C.-H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc. Natl. Acad. Sci. USA* **105**, 2070–2075 (2008).
- Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* **14**, 331–332 (2017).
- Zhang, K. Gctf: real-time CTF determination and correction. *J. Struct. Biol.* **193**, 1–12 (2015).
- Wagner, T. et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. *Commun. Biol.* **2**, 218 (2019).
- Scheres, S. H. W. RELION: Implementation of a Bayesian approach to cryo-EM structure determination. *J. Struct. Biol.* **180**, 519–530 (2012).
- Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D. Biol. Crystallogr.* **66**, 213–221 (2010).
- Wu, E. L. et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. *J. Comput. Chem.* **35**, 1997–2004 (2014).
- Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **1**, 19–25 (2015).
- Hoeser, J., Hong, S., Gehmann, G., Gennis, R. B. & Friedrich, T. Subunit CydX of *Escherichia coli* cytochrome *bd* ubiquinol oxidase is essential for assembly and stability of the di-heme active site. *FEBS Lett.* **588**, 1537–1541 (2014).



## Acknowledgements

We thank A. Hahn for valuable discussions. We thank H. Michel for support and providing infrastructural resources. We thank A. Kannt (Fraunhofer Leistungszentrum TheraNova) for helpful discussions. This work was supported by the Max Planck Society and the Nobel Laureate Fellowship of the Max Planck Society. G.H. acknowledges funding from CRC 1507 'Membrane-associated protein assemblies, machineries, and supercomplexes' of the Deutsche Forschungsgemeinschaft (DFG Project no. 450648163).

## Author contributions

D.W. purified CydDC, prepared grids, collected cryo-EM data, processed cryo-EM data, refined the structure, built the model, codrafted the manuscript and prepared figures. F.F. purified CydDC, prepared grids, collected cryo-EM data, performed biochemical activity assays, analyzed data and drafted figures. H.G.G. performed bacterial growth assays, determined oxygen consumption rates and collected UV-vis spectra. A.R.M. performed MD simulations, codrafted the manuscript and prepared figures. T.N.G. performed biochemical activity assays and analyzed data. R.R.G. optimized purification conditions and performed initial cryo-EM screening experiments. T.M.B.R. implemented purification and optimized CydDC buffer conditions. R.Z. assisted in cell culturing and protein purification. M.S. provided *pcydDC* and *pH85A*, and established the enzyme-coupled ATPase assay. S.W. calibrated and aligned the microscope. M.S. and S.S. initiated the project. G.H., D.B., M.S. and S.S. supervised the

project. S.S. designed research, evaluated data, funded the project, drafted the manuscript and generated figures.

## Funding

Open access funding provided by Max Planck Society

## Competing interests

The authors declare no competing interests.

## Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41589-023-01314-5>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41589-023-01314-5>.

**Correspondence and requests for materials** should be addressed to Schara Safarian.


**Peer review information** *Nature Chemical Biology* thanks Hongri Gong, Vivek Sharma and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).




**Extended Data Fig. 1 | GSH and L-Cys dependent ATPase activity of CydDC.** Effects of (a) GSH (0.01–1 mM) and (b) L-Cys (0.05–0.5 mM) on the ATPase activity of CydDC determined by a malachite green phosphate assay. All presented ATP

hydrolysis data are corrected for background activity in the absence of substrate candidates. Data are presented as mean values  $\pm$  s.d. (n = 3 assay technical replicates).




**Extended Data Fig. 2 | Influence of heme vs. thiols on the ATPase activity of CydDC. (a)** ATP hydrolysis activity of CydDC was determined in the presence of heme (500 nM), GSH (1 mM), and L-Cys (0.5 mM) using the malachite green phosphate and the PK/LDH coupled assays, respectively. Significance was assessed based on a paired two-tailed Student's *t*-test. Data are presented as mean values  $\pm$  s.d. ( $n = 3$  assay technical replicates). **(b, c)** Michaelis constants ( $K_M^{app}$ )

of CydDC for heme determined by malachite green phosphate (79.7 nM) and PK/LDH coupled assays (66.9 nM), respectively. All presented ATP hydrolysis data are corrected for background activity in the absence of substrate candidates. Data are presented as mean values  $\pm$  s.d. ( $n = 3$  assay technical replicates). Ns, not significant.




**Extended Data Fig. 3 | Mutant variants influence the ATPase activity of CydDC. (a)** Total ATPase activities of wild-type, H85A<sup>C</sup>, and E500Q<sup>C</sup> variants of CydDC show that unspecific background hydrolysis activity is slightly reduced by the histidine to alanine exchange of the characterized heme binding site, and strongly by the Walker B glutamate to glutamine exchange in NBS<sup>C</sup>. Total ATPase activity of wild-type CydDC in the presence and absence of GSH exemplifies a non-stimulatory effect. Data are presented as mean values  $\pm$ s.d. (n = 3 assay

technical replicates). **(b)** Heme (50–500 nM) dependent ATP hydrolysis activity of CydDC<sup>E500Q</sup> determined by malachite green phosphate assay. **(c)** Heme (50–500 nM) dependent ATP hydrolysis activity of CydDC<sup>H85A</sup> determined by malachite green phosphatase assay. All presented ATP hydrolysis data are corrected for background activity in the absence of heme. Data are presented as mean values  $\pm$ s.d. (n = 3 assay technical replicates).



**Extended Data Fig. 4 | Location and binding mode of heme in different CydDC conformations.** (a) Local density map of  $\text{OCc}_{\text{return}}^{\text{apo}}$ ,  $\text{IF}_{\text{asym}}^{\text{apo}}$ ,  $\text{IF}_{\text{bound}}^{\text{heme}}$ , and  $\text{IF}_{\text{coordinated}}^{\text{heme}}$  at the heme binding site shown in side and cross-section views.


(b) Heme models fitted into corresponding densities in maps of each conformational state. Density features of heme highlight that the heme molecule is rigidified during the process of binding and confinement.



### Extended Data Fig. 5 | Heme binding properties of *CydDC*<sup>wt</sup> and *CydDC*<sup>H85A</sup>.


(a) Size exclusion chromatograms (SEC) of *CydDC* (wt) in the absence and presence of exogenously added heme (applied before the experiment). Wild-type *CydDC* contains bound heme from native source, which co-migrates with the peak fraction of the protein. Addition of extra heme increases the intensity of the  $A_{410}$  signal indicating greater heme occupancy. (b) SEC of *CydDC*<sup>H85A</sup> in the absence and presence of exogenous heme (applied before the experiment). The chromatograms show that native heme does not copurify with the mutant

variant *CydDC*<sup>H85A</sup>. Furthermore, adding exogenous heme does not have the same effect observed with the wild-type *CydDC*. The slight increase in the  $A_{410}$  signal is attributed to heme molecules migrating into hydrophobic regions of detergent micelles. Relative ratios of the peak intensities between  $A_{410}$  (heme component) and  $A_{280}$  (protein component) are given. (c) Relative change of  $T_M$  in the absence and presence of exogenously added heme molecules to purified samples of *CydDC*<sup>wt</sup> and *CydDC*<sup>H85A</sup>. Data are presented as mean values  $\pm$  s.d. ( $n = 3$  assay technical replicates).



**Extended Data Fig. 6 | Heme partitions spontaneously into lipid bilayers.** (a) Molecular dynamics simulations show spontaneous binding and insertion of heme into a lipid bilayer composed of 70% POPE, 25% POPG, and 5% CL lipids. Heme establishes a stable position in the membrane during 100-ns simulation

runs. (b) During MD runs, position of the heme was tracked by the distance of the Fe atom to the center of the membrane in the Z-axis direction. Graph colors represent different simulation runs.




### Extended Data Fig. 7 | Conformational variety of nucleotide binding sites.

(a) Top panel: closeup view of NBS<sup>C</sup> conformations in the **IF<sub>confined</sub><sup>heme</sup>** (ATP), **Occ<sub>return</sub><sup>apo</sup>** (ADP + Pi), and **IF<sub>asymp</sub><sup>apo</sup>** (apo) states. Distances between the  $\gamma$ -phosphate and S487<sup>D</sup> (signature loop), and between K379<sup>C</sup> of the Walker A domain and S487<sup>D</sup> are indicated by dashed lines. Bottom panel: closeup view of NBS<sup>D</sup> conformations in the **IF<sub>confined</sub><sup>heme</sup>** (ATP), **Occ<sub>return</sub><sup>apo</sup>** (ATP), and **IF<sub>asymp</sub><sup>apo</sup>** (AMP-PNP) states. Distances between the  $\gamma$ -phosphates of ATP/AMP-PNP and S476<sup>C</sup> of the signature loop are


indicated by dashed lines. Conserved structural motifs of nucleotide binding and hydrolysis sites are highlighted. ATP, green; ADP, purple; AMP-PNP, gray; phosphate, orange; Mg<sup>2+</sup>, yellow. (b-d) Sequence alignments of the CydD and CydC NBDs from *E. coli*, *M. tb*, *M. smegmatis* and *B. subtilis* revealing the highly conserved motifs for ATP binding and hydrolysis. Highly conserved residues are highlighted in blue. Conserved amino acid groups are highlighted in gray.






**Extended Data Fig. 8 | Simulated outward-facing (OF) conformations of CydDC. (a)** Closeup views show residues involved in heme binding. Surface model cross-sections illustrate the changing shape and size of the internal cavity in different conformational states. Surface model side views highlight the change

in overall shape of the TMH region in different conformational states. **(b)** Closeup side views show changing orientations of TMs and heme-binding residues during conformational transitions of the predicted outward-facing states. Heme is shown as purple ball-and-stick model. EL<sup>D</sup> and TM4<sup>D</sup> are shown as tubes.



**Extended Data Fig. 9 | Transmembrane helix rearrangement during the proposed heme release mechanism.** Center: side views of CydDC TMH regions during heme confinement and release toward the periplasm. Left: cross-section views of TMH conformations at the level of the heme-binding site. Right:

cross-section views of TMH conformations at the level of the periplasmic gate. Distances between TM1 and 6 of CydD and CydC (critical for gate opening and closing) are indicated. Periplasmic loop regions are omitted for clarity.



**Extended Data Fig. 10 | Proposed model of heme transport facilitated by CydC.** Energy of ATP hydrolysis at NBD<sup>c</sup> converts CydC from the **IF<sup>heme\_confined</sup>** state to the **Occ<sup>apo\_return</sup>** state. Binding of heme to its dedicated pocket causes closing of the lateral substrate gate and triggers the release of ADP + Pi caused by conformational changes of the nucleotide-binding site of CydC. Release of heme occurs independent of ATP hydrolysis but requires binding of ATP. Separation of

TM lobes and rearrangement of residues around the heme-binding pocket cause the release of heme either towards the periplasmic space or to the periplasmic bilayer leaflet of the membrane. Conformations obtained by cryo-EM are shown as yellow and red schematic models. Conformations predicted by MD simulations are shown as light and dark gray models.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Titan Krios microscope operated at 300 kV and equipped with a BioQuantum energy filter and a K2/K3 camera (Gatan); Data collection quality was monitored through EPU v. 2.9-2.11 and CryoSPARC Live v3.0. UV-Vis spectra were recorded on a Varian Cary 50 UV-Vis Spectrophotometer. Thermal stabilities of purified CydDC variants were investigated with a Prometheus NT.48. Kinetic turnover of ATPase activity via the PK/LDH assay was monitored at 340 nm using the SpectraMax M2 Microplate Reader. For the Malachite green based phosphate assay, absorbance change at 620 nm was measured via a SpectraMax M2 Microplate Reader. Cell growth was monitored via a SpectraMax Plus 384 Microplate Reader.

Data analysis

ChimeraX v.1.13, MotionCor2-2.1.2.6, Gctf v. 1.06, CLUSTAL Omega v.1.2.4, RELION-3.1; CryoSPARC Live v3.0; COOT v. 0.8.9; Phenix (v. 1.14 & v. 1.18); MolProbity v. 4.5; CHARMM36m force field was used for protein, lipids, heme and ions, together with TIP3P water; Visual Molecular Dynamics (VMD) v. 1.9.2; GROMACS v. 2021.2; Jalview v. 2.11.2.0; TMalign v. 20210224; Spectroscopic data was analyzed via Origin Lab Pro 9.5, tunnels and cavities were mapped with MOLE 2.5; GraphPad v. 9.5.1 t-test calculator (<https://www.graphpad.com/quickcalcs/ttest1/?format=SD>).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Cryo-EM maps are deposited at the Electron Microscopy Data Bank under accession numbers: EMD-14636, EMD-14638, EMD-14639, EMD-14640, EMD-14641, EMD-14642, EMD-14643, EMD-14644, EMD-14645, EMD-14646, EMD-14647, EMD-14649, EMD-14652, EMD-14653, EMD-14654, EMD-14655, EMD-14656, EMD-14657, EMD-14659, EMD-14660, EMD-14662, EMD-14663, EMD-14665, EMD-14667, EMD-14668, EMD-14669, EMD-14670, EMD-14671, EMD-14672, EMD-14673, EMD-14674, EMD-14675, EMD-14676, EMD-14684, EMD-14689, EMD-15264, EMD-15265. Atomic models of CydDC have been deposited to the Protein Data Bank under accession numbers: 7ZD5, 7ZDA, 7ZDB, 7ZDC, 7ZDE, 7ZDF, 7ZDG, 7ZDK, 7ZDL, 7ZDR, 7ZDS, 7ZDT, 7ZDU, 7ZDV, 7ZDW, 7ZE5, 7ZEC. PDB models 6RKO and 7YO2 were used to generate figure 1f.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample sizes (number of collected micrographs) of respective cryo-EM datasets were chosen based on instrument availability and experimental design. Datasets of > 2000 micrographs ensured a sufficient number of particles to achieve resolutions < 3.5 Å. The smallest collected dataset contained 2294 micrographs (dataset 21) while the largest dataset contained 24110 micrographs (dataset 2). Oxygen consumption measurements and ATPase assays were performed in technical replicates (n = 3). Technical replicates were chosen to determine standard deviation values for each data points and to validate data quality.
Data exclusions	No data were excluded.
Replication	Single particle cryo-EM is based on averaging protein particles of nearly identical orientation within a vitreous layer of ice. Therefore, replication is not per se required to ensure statistical robustness of structural data. In case of this work, we have determined three individual structures of CydDC under 23 different sample conditions. Hence these data can be considered as biological replicates of the presented structural data.  Experimental findings of cell growth complementation, ATPase measurements, oxygen consumption measurements and thermal stability analyses were reproduced reliably.
Randomization	Generally, no randomization was required for the experimental design of this study. However, it is to note that particles are randomized during data processing steps in Relion-3.1 (randomization during 2D classification, randomized half sets during Refine3D). Randomized half sets of particles are used in final reconstruction steps in order to determined gold-standard Fourier shell correlations based on the 0.143 level.
Blinding	For all studies in this manuscript, such as 3D reconstruction, ATPase assays, or growth complementation, there was no awareness of group assignment that caused biased results, so blinding was relevant for data reliability.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials & experimental systems

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

## Methods

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging